Strumento inattivo

Altre lingue OYSR POIN

Azioni

OYST

US69242L1061

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Viatris Completes Acquisitions of Oyster Point Pharma, Famy Life Sciences	03/01/23
OYSTER POINT PHARMA, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	03/01/23
Oyster Point Pharma, Inc. Announces Board Resignations	03/01/23
Oyster Point Pharma, Inc.(NasdaqGS:OYST) dropped from NASDAQ Composite Index	03/01/23
Oyster Point Pharma, Inc.(NasdaqGS:OYST) dropped from S&P TMI Index	03/01/23
Viatris Inc. completed the acquisition of Oyster Point Pharma, Inc. from a group of shareholders.	03/01/23
Oyster Point Pharma, Inc.(NasdaqGS:OYST) dropped from S&P Global BMI Index	02/01/23
Oyster Point Pharma, Inc.(NasdaqGS:OYST) dropped from NASDAQ Biotechnology Index	16/12/22
OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST	07/12/22
Oyster Point Pharma Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635	05/12/22
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/12/22
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/12/22
OYSTER POINT PHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	10/11/22
Earnings Flash (OYST) OYSTER POINT PHARMA Reports Q3 Revenue $5.6M	10/11/22
Oyster Point Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22
Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights	10/11/22
Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights	10/11/22
North American Morning Briefing : Midterm Outcome -3-	09/11/22
OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST	09/11/22
OYSTER POINT PHARMA, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	08/11/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue OYSR POIN

Azioni

OYST

US69242L1061

Altre lingue

Filtri